Most recent by Robert H. Eckel, MD
Tirzepatide cuts risk for progression to type 2 diabetes for adults with prediabetes
Adults with prediabetes and overweight or obesity have a 94% lower risk for developing type 2 diabetes with the once-weekly GIP/GLP-1 dual agonist tirzepatide vs. placebo, according to top-line results from the SURMOUNT-1 3-year study.
SURMOUNT-2: Tirzepatide confers up to 15.7% weight loss for adults with obesity, diabetes
Adults with overweight or obesity and type 2 diabetes achieved a mean weight loss of more than 13% after taking either 10 mg or 15 mg of tirzepatide for 72 weeks, according to topline results from the SURMOUNT-2 trial.
Diabetes may be ‘no longer equivalent to CVD’ as a CV risk factor
Adults with diabetes in Ontario, Canada, had a greater reduction in risk for cardiovascular events from 1994 to 2014 compared with adults with prior CV disease, according to a research letter published in JAMA.
VIDEO: Cardiometabolic health management in older adults important
BOSTON — In this Healio video exclusive, a co-chair of the Cardiometabolic Health Congress discusses various highlights from the first 2.5 days of the meeting.
Weekly tirzepatide confers substantial weight loss in obesity without diabetes: SURMOUNT-1
NEW ORLEANS — Nearly all participants with obesity without diabetes assigned tirzepatide experienced at least 5% weight loss over 72 weeks compared with placebo, with at least 20% weight loss in more than half with the highest 15 mg dose.